AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2024
Jun 6, 2024
32883_dirs_2024-06-05_1d17ae1b-f66d-4b92-a0bb-95e5acb6e92d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2024-06-03
Reporting Person: Cittadine Andrew (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-03 | Common Stock | P | 12000 | $0.76 | Acquired | 105624 | Direct |
| 2024-06-04 | Common Stock | P | 12000 | $0.78 | Acquired | 117624 | Direct |
More from Monopar Therapeutics
Regulatory Filings
2026
May 29
Regulatory Filings
2026
May 19
Interim / Quarterly Report
2026
May 14
Report Publication Announcement
2026
May 14
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 1
Annual Report
2026
Mar 27
Director's Dealing
2026
Mar 4
Board/Management Information
2026
Mar 2